4月8日 -
** Longeveron LGVN.O股价盘前上涨6%至1.23美元
** 生物技术公司称在中国获得了一项专利，该专利涵盖了测量其干细胞产品强度和质量的测试，扩大了其全球专利保护范围。
** 专利有效期至2041年，涵盖间充质干细胞的效力测试，间充质干细胞是成人干细胞，用于帮助修复组织和减少炎症 - LGVN
** 补充说，测试适用于从骨髓、脂肪、血液、器官和实验室制造的干细胞中提取的干细胞，有助于确保疗法的安全性和有效性。
** 称该专利为其52项国际专利组合锦上添花
** Longeveron的主要实验疗法正在阿尔茨海默病、罕见小儿心脏病和老年性虚弱方面进行测试
** 截至上一交易日收盘，该公司股价已上涨近一倍
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.